60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

What happened

60 Degrees Pharmaceuticals said all five patients who completed tafenoquine-containing combination regimens in its expanded access study of relapsing babesiosis reported being much improved or very much improved, and each had negative conventional PCR test results for Babesia.

Confirmed

Global impact / market context

Babesiosis can persist or recur in immunosuppressed patients and can be life-threatening, so positive clinical and molecular results support further study of these regimens. However, this is a small expanded access study, not a controlled trial proving the drug works.

Analyst inference

60 Degrees is a small NASDAQ-listed pharmaceutical company developing medicines for vector-borne disease. Early-stage clinical updates can shift investor expectations for future trial spending and partnership prospects, but five patients is a very limited dataset for judging commercial potential.

Analyst inference

What to watch

1. Four of the five patients, or 80%, were also nonreactive on a highly sensitive blood-donor nucleic acid amplification test for Babesia performed on blood collected after treatment. Confirmed
2. Watch whether the company expands enrollment or advances tafenoquine-containing regimens into larger controlled studies, which would require added capital spending on trials and regulatory work. Proposed
3. The remaining patient had a reactive blood-donor NAT despite a negative follow-up conventional PCR result, so future data should clarify whether this reflects residual genetic material rather than active infection. Analyst inference

Evidence

• globenewswire.com